Follow AARDA
How You Can Help
Sign-up for Updates
Join Our Email List
Contact AARDA

National Office
22100 Gratiot Ave.
Eastpointe, MI 48021
586.776.3903 (fax)

Washington Office

Request Literature


  • Press Releases
  • Statistics
  • Awareness Campaign

Advocacy Issues

The American Autoimmune Related Diseases Association takes positions from time to time on health related issues and legislation and we provide information on issues facing the autoimmune community.

Comparative Effectiveness

NPC Releases 2014 Survey

  • In the coming years, we should expect to hear a good deal more about comparative effectiveness research (CER) and the work of the Patient-Centered Outcomes Research Institute (PCORI).  The concept of conducting research to determine which treatments and therapies are most effectiveness in addressing various health conditions is naturally of acute interest to the millions of Americans with autoimmune diseases.  It will be of significant interest to autoimmune patients that CER ensures that patients receive the most appropriate treatment which requires consideration of the variation in response of individual patients to specific treatments (e.g., treatment option B is more effective than A for some patients, yet A is more effective when measuring the average treatment response across patients).

    One of the keys to determining the ultimate impact of CER is understanding how the various players in the world of health care payment and delivery perceive his research and plan on utilizing it.  On this note, the National Pharmaceutical Council (NPC) has performed an important service.

    The NPC has just released its 2014 survey of payers, government officials, health researchers and other essential health care stakeholders on the subject of CER, PCORI and their potential impact on health care decision-making.  This survey is a “must read” for anyone interested in the ongoing evolution of the health care system and how patients stand to be affected.

    Among its findings, the NPC survey tells us that health care stakeholders believe the full impact of CER is still on the horizon and that PCORI is viewed as an important player in prioritizing, funding and disseminating research.  There is much more within the publication itself, but the bottom line is a reaffirmation that this research is likely to have an impact on the health care system and the patients who rely upon it.



AARDA on Facebook